



Medicines Information: Product details

Search SPC and PILs

Enter a product or active substance:

Search

This page shows the Summary of Product Characteristics (SPC) and patient information leaflet (PIL) for the product.

Before a medicine can be sold in the UK, a number of licences are essential. Products with a UK marketing authorisation have a licence number in the format 'PL 12345/0001'. The first two characters are always the letters 'PL'. The product licence number can be found on the packaging of the product. You can identify the product in the list below using the PL number in the links below.

Please read the following information and tick the box to proceed to view the product information in pdf format.

Disclaimer:

I understand that this information is a copy of the Summary of Product Characteristics and patient information leaflet for a medicine, which outline the conditions under which the medicine should be used and information on its known safety.

I understand that this information may be updated several times within its shelf life, and that there could be differences between the version of the information shown here and other information in the public domain.

I understand that the MHRA is unable to offer medical advice and that if a patient has any questions about a medicine they are taking they should contact their doctor or pharmacist. Patients should not stop taking any prescribed medicines without first speaking to a healthcare professional. Suspected adverse reactions to a medicine can be reported to us on a [Yellow Card](#)

I understand that the MHRA has used its best endeavours in publishing this information, but accept that the information may not be the most up to date version for this product.

To view details for **MEDRONE TABLETS 16MG**, please read and accept the disclaimer or [go back to product listing](#).

☒ I have read and understand the disclaimer.

Product Name: **MEDRONE TABLETS 16MG**

1. [LEAFLET MAH BRAND_PL 00057-1479.PDF](#)  (79KB)

2. [SPC-DOC_PL 00057-1479.PDF](#)  (93KB)

|||||

© Crown Copyright 2017

Head office: 151 Buckingham Palace Road, Victoria, London, SW1W 9SZ
General enquiries: info@mhra.gov.uk

Medicines and Healthcare
Products Regulatory Agency



INVESTORS IN PEOPLE

SUMMARY OF PRODUCT CHARACTERISTICS

1 NAME OF THE MEDICINAL PRODUCT

Medrone Tablets 16 mg

2 QUALITATIVE AND QUANTITATIVE COMPOSITION

Each Medrone Tablet contains 16 mg methylprednisolone.

Excipients with known effect:

Lactose, sucrose

For the full list of excipients, see section 6.1.

3 PHARMACEUTICAL FORM

Tablet.

White elliptical, convex tablet, cross-scored on one side and marked "UPJOHN 73" on the other. The score-lines are non functional and cannot be used to split the tablet into equal doses.

4 CLINICAL PARTICULARS

4.1 Therapeutic indications

Medrone is indicated for conditions requiring glucocorticoid activity such as:-

1. Endocrine disorders
Primary and secondary adrenal insufficiency
Congenital adrenal hyperplasia
2. Rheumatic disorders
Rheumatoid arthritis
Juvenile chronic arthritis
Ankylosing spondylitis
3. Collagen diseases/arthritis
Systemic lupus erythematosus
Systemic dermatomyositis (polymyositis)
Rheumatic fever with severe carditis
Giant cell arteritis/polymyalgia rheumatica
4. Dermatological diseases

Pemphigus vulgaris

5. Allergic states
Severe seasonal and perennial allergic rhinitis
Drug hypersensitivity reactions
Serum sickness
Allergic contact dermatitis
Bronchial asthma
6. Ophthalmic diseases
Anterior uveitis (iritis, iridocyclitis)
Posterior uveitis
Optic neuritis
7. Respiratory diseases
Pulmonary sarcoid
Fulminating or disseminated tuberculosis (with appropriate anti-tuberculous chemotherapy)
Aspiration of gastric contents
8. Haematological disorders
Idiopathic thrombocytopenic purpura
Haemolytic anaemia (autoimmune)
9. Neoplastic diseases
Leukaemia (acute and lymphatic)
Malignant lymphoma
10. Gastro-intestinal diseases
Ulcerative colitis
Crohn's disease
11. Miscellaneous
Tuberculous meningitis (with appropriate antituberculous chemotherapy)
Transplantation

4.2 Posology and method of administration

The dosage recommendations shown in the table below are suggested initial daily doses and are intended as guides. The average total daily dose recommended may be given either as a single dose or in divided doses (excepting in alternate day therapy when the minimum effective daily dose is doubled and given every other day at 8.00 am).

Undesirable effects may be minimised by using the lowest effective dose for the minimum period (see section 4.4).

The initial suppressive dose level may vary depending on the condition being treated. This is continued until a satisfactory clinical response is obtained, a period usually of three to seven days in the case of rheumatic diseases (except for acute rheumatic carditis), allergic conditions affecting the skin or

respiratory tract and ophthalmic diseases. If a satisfactory response is not obtained in seven days, re-evaluation of the case to confirm the original diagnosis should be made. As soon as a satisfactory clinical response is obtained, the daily dose should be reduced gradually, either to termination of treatment in the case of acute conditions (e.g. seasonal asthma, exfoliative dermatitis, acute ocular inflammations) or to the minimal effective maintenance dose level in the case of chronic conditions (e.g. rheumatoid arthritis, systemic lupus erythematosus, bronchial asthma, atopic dermatitis). In chronic conditions, and in rheumatoid arthritis especially, it is important that the reduction in dosage from initial to maintenance dose levels be accomplished as clinically appropriate. Decrements of not more than 2 mg at intervals of 7 - 10 days are suggested. In rheumatoid arthritis, maintenance steroid therapy should be at the lowest possible level.

In alternate-day therapy, the minimum daily corticoid requirement is doubled and administered as a single dose every other day at 8.00 am. Dosage requirements depend on the condition being treated and response of the patient.

Elderly patients: Treatment of elderly patients, particularly if long-term, should be planned bearing in mind the more serious consequences of the common side-effects of corticosteroids in old age, particularly osteoporosis, diabetes, hypertension, susceptibility to infection and thinning of skin (see section 4.4).

Paediatric population: In general, dosage for children should be based upon clinical response and is at the discretion of the physician. Treatment should be limited to the minimum dosage for the shortest period of time. If possible, treatment should be administered as a single dose on alternate days (see section 4.4).

Dosage Recommendations:

<u>Indications</u>	<u>Recommended initial daily dosage</u>
Rheumatoid arthritis	
severe	12 - 16 mg
moderately severe	8 - 12 mg
moderate	4 - 8 mg
children	4 - 8 mg
Systemic dermatomyositis	48 mg
Systemic lupus erythematosus	20 - 100 mg
Acute rheumatic fever	48 mg until ESR normal for one week.
Allergic diseases	12 - 40 mg
Bronchial asthma	up to 64 mg single dose/alternate day up to 100 mg maximum.
Ophthalmic diseases	12 - 40 mg
Haematological disorders and leukaemias	16 - 100 mg

Malignant lymphoma	16 - 100 mg
Ulcerative colitis	16 - 60 mg
Crohn's disease	up to 48 mg per day in acute episodes.
Organ transplantation	up to 3.6 mg/kg/day
Pulmonary sarcoid	32 - 48 mg on alternate days.
Giant cell arteritis/polymyalgia rheumatica	64 mg
Pemphigus vulgaris	80 - 360 mg

4.3 Contraindications

Methylprednisolone tablets are contraindicated:

- in patients who have systemic fungal infections
- in patients who have systemic infections unless specific anti-infective therapy is employed
- in patients who have hypersensitivity to the active substance or to any of the excipients listed in section 6.1

Administration of live or live, attenuated vaccines is contraindicated in patients receiving immunosuppressive doses of corticosteroids.

4.4 Special warnings and precautions for use

Immunosuppressant Effects/Increased Susceptibility to Infections

Corticosteroids may increase susceptibility to infection, may mask some signs of infection, and new infections may appear during their use. Suppression of the inflammatory response and immune function increases the susceptibility to fungal, viral and bacterial infections and their severity. The clinical presentation may often be atypical and may reach an advanced stage before being recognised.

Persons who are on drugs which suppress the immune system are more susceptible to infections than healthy individuals. Chicken pox and measles, for example, can have a more serious or even fatal course in non-immune children or adults on corticosteroids.

Chickenpox is of serious concern since this normally minor illness may be fatal in immunosuppressed patients. Patients (or parents of children) without a definite history of chickenpox should be advised to avoid close personal contact with chickenpox or herpes zoster and if exposed they should seek urgent medical attention. Passive immunization with varicella/zoster immunoglobulin (VZIG) is needed by exposed non-immune patients who are receiving systemic corticosteroids or who have used them within the previous 3 months; this should be given within 10 days of exposure to chickenpox. If a diagnosis of chickenpox is confirmed, the illness warrants specialist care and urgent treatment. Corticosteroids should not be stopped and the dose may need to be increased.

Exposure to measles should be avoided. Medical advice must be sought immediately if exposure occurs. Prophylaxis with normal intramuscular immunoglobulin may be needed.

Similarly corticosteroids should be used with great care in patients with known or suspected parasitic infections such as *Strongyloides* (threadworm) infestation, which may lead to *Strongyloides* hyperinfection and dissemination with widespread larval migration, often accompanied by severe enterocolitis and potentially fatal gram-negative septicemia.

Administration of live or live, attenuated vaccines is contraindicated in patients receiving immunosuppressive doses of corticosteroids. The antibody response to other vaccines may be diminished.

The use of corticosteroids in active tuberculosis should be restricted to those cases of fulminating or disseminated tuberculosis in which the corticosteroid is used for the management of the disease in conjunction with an appropriate antituberculous regimen. If corticosteroids are indicated in patients with latent tuberculosis or tuberculin reactivity, close observation is necessary as reactivation of the disease may occur. During prolonged corticosteroid therapy, these patients should receive chemoprophylaxis.

Kaposi's sarcoma has been reported to occur in patients receiving corticosteroid therapy. Discontinuation of corticosteroids may result in clinical remission.

The role of corticosteroids in septic shock has been controversial, with early studies reporting both beneficial and detrimental effects. More recently, supplemental corticosteroids have been suggested to be beneficial in patients with established septic shock who exhibit adrenal insufficiency. However, their routine use in septic shock is not recommended. A systematic review of short-course high-dose corticosteroids did not support their use. However, meta-analyses, and a review have suggested that longer courses (5-11 days) of low-dose corticosteroids might reduce mortality.

Immune System

Because rare instances of skin reactions and anaphylactic/anaphylactoid reactions have occurred in patients receiving corticosteroid therapy, appropriate precautionary measures should be taken prior to administration, especially when the patient has a history of allergy to any drug.

Endocrine Effects

In patients on corticosteroid therapy subjected to unusual stress, increased dosage of rapidly acting corticosteroids before, during, and after the stressful situation is indicated.

Adrenal cortical atrophy develops during prolonged therapy and may persist for months after stopping treatment. In patients who have received more than physiological doses of systemic corticosteroids (approximately 6 mg methylprednisolone) for greater than 3 weeks, withdrawal should not be abrupt. How dose reduction should be carried out depends largely on whether the disease is likely to relapse as the dose of systemic corticosteroids is reduced. Clinical assessment of disease activity may be needed during withdrawal. If the disease is unlikely to relapse on withdrawal of systemic corticosteroids, but there is uncertainty about HPA suppression, the dose of systemic corticosteroid may be reduced rapidly to physiological doses. Once a daily dose of 6 mg methylprednisolone is reached, dose reduction should be slower to allow the HPA-axis to recover.

Abrupt withdrawal of systemic corticosteroid treatment, which has continued up to 3 weeks is appropriate if it is considered that the disease is unlikely to relapse. Abrupt withdrawal of doses up to 32 mg daily of methylprednisolone for 3 weeks is unlikely to lead to clinically relevant HPA-axis suppression, in the majority of patients. In the following patient groups, gradual withdrawal of systemic corticosteroid therapy should be considered even after courses lasting 3 weeks or less:

- Patients who have had repeated courses of systemic corticosteroids, particularly if taken for greater than 3 weeks.
- When a short course has been prescribed within one year of cessation of long-term therapy (months or years).
- Patients who may have reasons for adrenocortical insufficiency other than exogenous corticosteroid therapy. In addition, acute adrenal insufficiency leading to a fatal outcome may occur if glucocorticoids are withdrawn abruptly.
- Patients receiving doses of systemic corticosteroid greater than 32 mg daily of methylprednisolone.
- Patients repeatedly taking doses in the evening.

A steroid “withdrawal syndrome,” seemingly unrelated to adrenocortical insufficiency, may also occur following abrupt discontinuance of glucocorticoids. This syndrome includes symptoms such as: anorexia, nausea, vomiting, lethargy, headache, fever, joint pain, desquamation, myalgia, weight loss, and/or hypotension. These effects are thought to be due to the sudden change in glucocorticoid concentration rather than to low corticosteroid levels.

Glucocorticoids can produce or aggravate Cushing’s syndrome, therefore glucocorticoids should be avoided in patients with Cushing’s disease.

Particular care is required when considering the use of systemic corticosteroids in patients with hypothyroidism and frequent patient monitoring is necessary.

Metabolism and Nutrition Disorders

Corticosteroids, including methylprednisolone, can increase blood glucose, worsen pre-existing diabetes, and predispose those on long-term corticosteroid therapy to diabetes mellitus.

Particular care is required when considering the use of systemic corticosteroids in patients with Diabetes mellitus (or a family history of diabetes) and frequent patient monitoring is necessary.

Psychiatric Effects

Patients and/or carers should be warned that potentially severe psychiatric adverse reactions may occur with systemic steroids (see section 4.8). Symptoms typically emerge within a few days or weeks of starting treatment. Risks may be higher with high doses/systemic exposure (see also section 4.5), although dose levels do not allow prediction of the onset, type, severity or duration of reactions. Most reactions recover after either dose reduction or withdrawal, although specific treatment may be necessary.

Patients/carers should be encouraged to seek medical advice if worrying psychological symptoms develop, especially if depressed mood or suicidal ideation is suspected. Patients/carers should be alert to possible psychiatric disturbances that may occur either during or immediately after dose tapering/withdrawal of systemic steroids, although such reactions have been reported infrequently.

Particular care is required when considering the use of systemic corticosteroids in patients with existing or previous history of severe affective disorders in themselves or in their first degree relatives. These would include depressive or manic-depressive illness and previous steroid psychosis.

Nervous System Effects

Particular care is required when considering the use of systemic corticosteroids in patients with seizure disorders and myasthenia gravis (see myopathy statement in Musculoskeletal Effects section) and frequent patient monitoring is necessary.

There have been reports of epidural lipomatosis in patients taking corticosteroids, typically with long-term use at high doses.

Ocular Effects

Particular care is required when considering the use of systemic corticosteroids in patients with glaucoma (or a family history of glaucoma) and ocular herpes simplex as there is a fear of corneal perforation, and frequent patient monitoring is necessary.

Prolonged use of corticosteroids may produce posterior subcapsular cataracts and nuclear cataracts (particularly in children), exophthalmos or increased intraocular pressure, which may result in glaucoma with possible damage to the optic nerves.

Secondary fungal and viral infections of the eye may also be enhanced in patients receiving glucocorticoids.

Corticosteroid therapy has been associated with chorioretinopathy, which may lead to retinal detachment.

Cardiac Events

Adverse effects of glucocorticoids on the cardiovascular system, such as dyslipidemia and hypertension, may predispose treated patients with existing cardiovascular risk factors to additional cardiovascular effects, if high doses and prolonged courses are used. Accordingly, corticosteroids should be employed judiciously in such patients and attention should be paid to risk modification and additional cardiac monitoring if needed. Low dose and alternate day therapy may reduce the incidence of complications in corticosteroid therapy.

Systemic corticosteroids should be used with caution, and only if strictly necessary, in cases of congestive heart failure.

Particular care is required when considering the use of systemic corticosteroids in patients with recent myocardial infarction (myocardial rupture has been reported) and frequent patient monitoring is necessary.

Care should be taken for patients receiving cardioactive drugs such as digoxin because of steroid induced electrolyte disturbance/potassium loss (see section 4.8).

Vascular Effects

Particular care is required when considering the use of systemic corticosteroids in patients with the following conditions and frequent patient monitoring is necessary.

- Hypertension

- Predisposition to thrombophlebitis

Thrombosis including venous thromboembolism has been reported to occur with corticosteroids. As a result corticosteroids should be used with caution in patients who have or may be predisposed to thromboembolic disorders.

Gastrointestinal Effects

High doses of corticosteroids may produce acute pancreatitis.

Particular care is required when considering the use of systemic corticosteroids in patients with the following conditions and frequent patient monitoring is necessary.

- Peptic ulceration.

- Fresh intestinal anastomoses.

- Abscess or other pyogenic infections.

- Ulcerative colitis.

- Diverticulitis.

Glucocorticoid therapy may mask peritonitis or other signs or symptoms associated with gastrointestinal disorders such as perforation, obstruction or pancreatitis. In combination with NSAIDs, the risk of developing gastrointestinal ulcers is increased.

Hepatobiliary Effects

Particular care is required when considering the use of systemic corticosteroids in patients with liver failure or cirrhosis and frequent patient monitoring is necessary.

Rarely hepatobiliary disorders were reported, in the majority of these cases, they were reversible after withdrawal of therapy. Therefore appropriate monitoring is required.

Musculoskeletal Effects

An acute myopathy has been reported with the use of high doses of corticosteroids, most often occurring in patients with disorders of neuromuscular transmission (e.g. myasthenia gravis), or in patients receiving concomitant therapy with anticholinergics, such as neuromuscular blocking drugs (e.g. pancuronium). This acute myopathy is generalized, may involve ocular and respiratory muscles, and may result in quadriparesis. Elevations of creatine kinase may occur. Clinical improvement or recovery after stopping corticosteroids may require weeks to years.

Particular care is required when considering the use of systemic corticosteroids in patients with osteoporosis (post-menopausal females are particularly at risk) and frequent patient monitoring is necessary.

Renal and Urinary

Particular care is required when considering the use of systemic corticosteroids in patients with renal insufficiency and frequent patient monitoring is necessary.

Injury, poisoning and procedural complications

Systemic corticosteroids are not indicated for, and therefore should not be used to treat, traumatic brain injury, a multicenter study revealed an increased mortality at 2 weeks and 6 months after injury in patients administered methylprednisolone sodium succinate compared to placebo. A causal association with methylprednisolone sodium succinate treatment has not been established.

Other

Undesirable effects may be minimised by using the lowest effective dose for the minimum period, and by administering the daily requirement as a single morning dose or whenever possible as a single morning dose on alternative days. Frequent patient review is required to appropriately titrate the dose against disease activity (see section 4.2).

Patients should carry 'Steroid Treatment' cards which give clear guidance on the precautions to be taken to minimise risk and which provide details of prescriber, drug, dosage and the duration of treatment.

Co-treatment with CYP3A inhibitors, including cobicistat-containing products, is expected to increase the risk of systemic side-effects. The combination should be avoided unless the benefit outweighs the increased risk of systemic corticosteroid side-effects, in which case patients should be monitored for systemic corticosteroid side-effects (see section 4.5).

Aspirin and non-steroidal anti-inflammatory agents should be used cautiously in conjunction with corticosteroids.

Pheochromocytoma crisis, which can be fatal, has been reported after administration of systemic corticosteroids. Corticosteroids should only be administered to patients with suspected or identified pheochromocytoma after an appropriate risk/benefit evaluation.

Paediatric population: Corticosteroids cause growth retardation in infancy, childhood and adolescence. Growth and development of infants and children on prolonged corticosteroid therapy should be carefully observed. Treatment should be limited to the minimum dosage for the shortest possible time. In order to minimise suppression of the hypothalamo-pituitary-adrenal axis and growth retardation, treatment should be administered where possible as a single dose on alternate days (see section 4.2).

Infants and children on prolonged corticosteroid therapy are at special risk from raised intracranial pressure.

High doses of corticosteroids may produce pancreatitis in children.

Use in the elderly: The common adverse effects of systemic corticosteroids may be associated with more serious consequences in old age, especially osteoporosis, hypertension, hypokalaemia, diabetes, susceptibility to infection and thinning of the skin. Close clinical supervision is required to avoid life-threatening reactions.

Ingredient warning

This medicine contains lactose. Patients with rare hereditary problems of galactose intolerance, the Lapp lactase deficiency or glucose-galactose malabsorption should not take this medicine.

This medicine contains sucrose. Patients with rare hereditary problems of fructose intolerance, glucose-galactose malabsorption or sucrase-isomaltase insufficiency should not take this medicine.

4.5 Interaction with other medicinal products and other forms of interaction

Methylprednisolone is a cytochrome P450 enzyme (CYP) substrate and is mainly metabolized by the CYP3A4 enzyme. CYP3A4 is the dominant enzyme of the most abundant CYP subfamily in the liver of adult humans. It catalyzes 6 β -hydroxylation of steroids, the essential Phase I metabolic step for both endogenous and synthetic corticosteroids. Many other compounds are also substrates of CYP3A4, some of which (as well as other drugs) have been shown to alter glucocorticoid metabolism by induction (upregulation) or inhibition of the CYP3A4 enzyme.

Drug Class or Type - DRUG or SUBSTANCE	Interaction	Effect
Antibiotic, Antitubercular - RIFAMPIN - RIFABUTIN	CYP3A4 Inducer	CYP3A4 INDUCERS - Drugs that induce CYP3A4 activity generally increase hepatic clearance, resulting in decreased plasma concentration of medications that are substrates for CYP3A4. Co-administration may require an increase in methylprednisolone dosage to achieve the desired result.
Anticonvulsants - PHENOBARBITAL - PHENYTOIN - PRIMIDONE		
Anticonvulsant - CARBAMAZEPINE	CYP3A4 Inducer (and Substrate)	CYP3A4 INDUCERS – see box above CYP3A4 SUBSTRATES - In the presence of another CYP3A4 substrate, the hepatic clearance of methylprednisolone may be affected, with corresponding dosage adjustments required. It is possible that adverse events associated with the use of either drug alone may be more likely to occur with co-administration.
Macrolide Antibacterial - TROLEANDOMYCIN	CYP3A4 Inhibitor	CYP3A4 INHIBITORS - Drugs that inhibit CYP3A4 activity generally decrease hepatic clearance and increase the plasma concentration of CYP3A4 substrate medications, such
- GRAPEFRUIT JUICE		

Calcium Antagonist - MIBEFRADIL		
Histamine H ₂ receptor Antagonist - CIMETIDINE		
Antibacterial - ISONIAZID		In addition, there is a potential effect of methylprednisolone to increase the acetylation rate and clearance of isoniazid.
Antiemetic - APREPITANT - FOSAPREPITANT	CYP3A4 Inhibitor (and Substrate)	CYP3A4 INHIBITORS – see box above CYP3A4 SUBSTRATES - In the presence of another CYP3A4 substrate, the hepatic clearance of methylprednisolone may be affected, with corresponding dosage adjustments required. It is possible that adverse events associated with the use of either drug alone may be more likely to occur with co-administration. (1) Mutual inhibition of metabolism occurs with concurrent use of ciclosporin and methylprednisolone, which may increase the plasma concentrations of either or both drugs. Therefore, it is possible that adverse events associated with the use of either drug alone may be more likely to occur upon co-administration. (2) Protease inhibitors, such as indinavir and ritonavir, may increase plasma concentrations of corticosteroids. (3) Corticosteroids may induce the metabolism of HIV-protease inhibitors resulting in reduced plasma concentrations.
Antifungal - ITRACONAZOLE - KETOCONAZOLE		
Calcium Channel Blocker - DILTIAZEM		
Contraceptives (oral) - ETHINYLESTRADIOL/ NORETHINDRONE		
Immunosuppressant - CICLOSPORIN (1)		
Macrolide Antibacterial - CLARITHROMYCIN - ERYTHROMYCIN		
Antivirals - HIV-PROTEASE INHIBITORS (2) (3)		
Pharmacokinetic enhancers -COBICISTAT		

Immunosuppressant - CYCLOPHOSPHAMIDE - TACROLIMUS	CYP3A4 Substrate	CYP3A4 SUBSTRATES - In the presence of another CYP3A4 substrate, the hepatic clearance of methylprednisolone may be affected, with corresponding dosage adjustments required. It is possible that adverse events associated with the use of either drug alone may be more likely to occur with co-administration.
NSAIDs (nonsteroidal anti-inflammatory drugs) (4) - high-dose ASPIRIN (5) (acetylsalicylic acid)	Non-CYP3A4-mediated effects	(4) There may be increased incidence of gastrointestinal bleeding and ulceration when corticosteroids are given with NSAIDs. (5) Methylprednisolone may increase the clearance of high-dose aspirin, which can lead to decreased salicylate serum levels. Discontinuation of methylprednisolone treatment can lead to raised salicylate serum levels, which could lead to an increased risk of salicylate toxicity.
Anticholinergics (6) - NEUROMUSCULAR BLOCKERS (7)		(6) An acute myopathy has been reported with the concomitant use of high doses of corticosteroids and anticholinergics, such as neuromuscular blocking drugs. (See section 4.4 Musculoskeletal, for additional information.) (7) Antagonism of the neuromuscular blocking effects of pancuronium and vecuronium has been reported in patients taking corticosteroids. This interaction may be expected with all competitive neuromuscular blockers.
Anticholinesterases		Steroids may reduce the effects of anticholinesterases in myasthenia gravis.
Anti-diabetics		Because corticosteroids may increase blood glucose concentrations, dosage adjustments of anti-diabetic agents may be required.
Anticoagulants (oral)		The efficacy of coumarin anticoagulants may be enhanced by concurrent corticosteroid therapy and close monitoring of the INR or prothrombin time is required to avoid spontaneous bleeding.

Potassium-depleting agents		When corticosteroids are administered concomitantly with potassium-depleting agents (i.e. diuretics), patients should be observed closely for development of hypokalaemia. There is also an increased risk of hypokalaemia with concurrent use of corticosteroids with amphotericin B, xanthenes, or beta2 agonists.
Aromatase inhibitors -AMINOGLUTETHIMIDE		Aminoglutethimide-induced adrenal suppression may exacerbate endocrine changes caused by prolonged glucocorticoid treatment.

4.6 Fertility, pregnancy and lactation

Fertility

Corticosteroids have been shown to impair fertility in animal studies (see section 5.3).

Pregnancy

The ability of corticosteroids to cross the placenta varies between individual drugs, however, methylprednisolone does cross the placenta. In humans, the risk of low birth weight appears to be dose related and may be minimized by administering lower corticosteroid doses.

Administration of corticosteroids to pregnant animals can cause abnormalities of foetal development including cleft palate, intra-uterine growth retardation and effects on brain growth and development. There is no evidence that corticosteroids result in an increased incidence of congenital abnormalities, such as cleft palate in man, however, when administered for long periods or repeatedly during pregnancy, corticosteroids may increase the risk of intra-uterine growth retardation. Infants born to mothers, who have received substantial doses of corticosteroids during pregnancy must be carefully observed and evaluated for signs of adrenal insufficiency. Hypoadrenalism may, in theory, occur in the neonate following prenatal exposure to corticosteroids but usually resolves spontaneously following birth and is rarely clinically important.

Since adequate human reproductive studies have not been done with methylprednisolone, this medicinal product, as with all drugs, should be used during pregnancy only after a careful assessment of the benefit-risk ratio to the mother, embryo, foetus or child. When corticosteroids are essential, however, patients with normal pregnancies may be treated as though they were in the non-gravid state.

Cataracts have been observed in infants born to mothers undergoing long-term treatment with corticosteroids during pregnancy.

Breast-feeding

Corticosteroids are excreted in small amounts in breast milk, however, doses of up to 40 mg daily of methylprednisolone are unlikely to cause systemic effects in the infant. Infants of mothers taking higher doses than this may have a degree of adrenal suppression. This medicinal product should be used during breast feeding only after a careful assessment of the benefit-risk ratio to the mother and infant.

4.7 Effects on ability to drive and use machines

The effect of corticosteroids on the ability to drive or use machinery has not been systematically evaluated. Undesirable effects, such as dizziness, vertigo, visual disturbances and fatigue are possible after treatment with corticosteroids. If affected, patients should not drive or operate machinery.

4.8 Undesirable effects

MedDRA System Organ Class	Frequency†	Undesirable Effects
<i>Infections and infestations</i>	<i>Common</i>	Infection (including increased susceptibility and severity of infections with suppression of clinical symptoms and signs)
	<i>Not Known</i>	Opportunistic infection; recurrence of dormant tuberculosis; Peritonitis
<i>Blood and lymphatic system disorders</i>	<i>Not Known</i>	Leukocytosis
<i>Immune system disorders</i>	<i>Not Known</i>	Drug hypersensitivity Anaphylactic reaction Anaphylactoid reaction
<i>Endocrine disorders</i>	<i>Common</i>	Cushingoid
	<i>Not Known</i>	Hypopituitarism
<i>Neoplasms benign, malignant and unspecified (including cysts and polyps)</i>	<i>Not Known</i>	Kaposi's sarcoma
<i>Metabolism and nutrition disorders</i>	<i>Common</i>	Sodium retention; Fluid retention
	<i>Not Known</i>	Metabolic acidosis; Alkalosis hypokalaemic; Dyslipidaemia; Glucose tolerance impaired; increased requirements for insulin (or oral hypoglycemic agents in diabetics); Lipomatosis; Increased appetite (which may result in Weight increased); Epidural lipomatosis
<i>Psychiatric disorders</i>	<i>Common</i>	Affective disorder (including Depressed mood and Euphoric mood)
	<i>Not Known</i>	Psychotic disorder (including Mania, Delusion, Hallucination, and Schizophrenia; Psychotic behaviour; Affective disorder (including Affect lability, Psychological dependence, Suicidal ideation); Mental disorder; Personality change; Confusional state; Anxiety; Mood swings; Abnormal behaviour; Insomnia; Irritability
<i>Nervous system disorders</i>	<i>Not Known</i>	Intracranial pressure increased (with Papilloedema [Benign intracranial hypertension]); Seizure; Amnesia; Cognitive disorder; Dizziness; Headache

<i>Eye disorders</i>	<i>Common</i>	Cataract
	<i>Not Known</i>	Glaucoma; Exophthalmos; Corneal thinning; Scleral thinning; Chorioretinopathy
<i>Ear and labyrinth disorders</i>	<i>Not Known</i>	Vertigo
<i>Cardiac disorders</i>	<i>Not Known</i>	Cardiac failure congestive (in susceptible patients); Myocardial rupture following myocardial infarction
<i>Vascular disorders</i>	<i>Common</i>	Hypertension
	<i>Not Known</i>	Hypotension; Embolism arterial; Thrombotic events
<i>Respiratory, thoracic and mediastinal disorders</i>	<i>Not Known</i>	Pulmonary embolism, Hiccups
<i>Gastrointestinal disorders</i>	<i>Common</i>	Peptic ulcer (with possible Peptic ulcer perforation and Peptic ulcer haemorrhage)
	<i>Not Known</i>	Intestinal perforation; Gastric haemorrhage; Pancreatitis; Oesophagitis ulcerative; Oesophagitis; Abdominal distension; Abdominal pain; Diarrhoea; Dyspepsia; Nausea
<i>Hepatobiliary disorders</i>	<i>Not Known</i>	Increase of liver enzymes (e.g alanine aminotransferase increased, aspartate aminotransferase increased)
<i>Skin and subcutaneous tissue disorders</i>	<i>Common</i>	Skin atrophy; Acne
	<i>Not Known</i>	Angioedema; Hirsutism; Petechiae; Ecchymosis; Erythema; Hyperhidrosis; Skin striae; Rash; Pruritus; Urticaria; Telangiectasia
<i>Musculoskeletal and connective tissue disorders</i>	<i>Common</i>	Muscular weakness; Growth retardation
	<i>Not Known</i>	Myalgia; Myopathy; Muscle atrophy; Osteoporosis; Osteonecrosis; Pathologic fracture; Neuropathic arthropathy; Arthralgia
<i>Reproductive system and breast disorders</i>	<i>Not Known</i>	Menstruation irregular
<i>General disorders and administration site conditions</i>	<i>Common</i>	Impaired healing
	<i>Not Known</i>	Oedema peripheral; Fatigue; Malaise; Withdrawal symptoms - too rapid a reduction of corticosteroid dosage following prolonged treatment can lead to acute adrenal insufficiency, hypotension and death (see section 4.4)
<i>Investigations</i>	<i>Common</i>	Blood potassium decreased
	<i>Not Known</i>	Intraocular pressure increased; Carbohydrate tolerance decreased; Urine calcium increased; Blood alkaline phosphatase increased; Urine calcium increased; Suppression of reactions to skin tests

<i>Injury, poisoning and procedural complications</i>	<i>Not Known</i>	Tendon rupture (particularly of the Achilles tendon); Spinal compression fracture
--	-------------------------	---

[†] Peritonitis may be the primary presenting sign or symptom of a gastrointestinal disorder such as perforation, obstruction or pancreatitis (see section 4.4)

Common ($\geq 1/100$ to $< 1/10$); Uncommon ($\geq 1/1,000$ to $< 1/100$); Rare ($\geq 1/10,000$ to $< 1/1,000$); Not known (frequency cannot be estimated from the available data)

The incidence of predictable undesirable side-effects associated with the use of corticosteroids, including hypothalamic-pituitary-adrenal suppression correlates with the relative potency of the drug, dosage, timing of administration and duration of treatment (see section 4.4).

Reporting of suspected adverse reactions

Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the Yellow Card Scheme at www.mhra.gov.uk/yellowcard.

4.9 Overdose

Administration of methylprednisolone should not be discontinued abruptly but tailed off over a period of time. Appropriate action should be taken to alleviate the symptoms produced by any side-effect that may become apparent. It may be necessary to support the patient with corticosteroids during any further period of trauma occurring within two years of overdose.

There is no clinical syndrome of acute overdose with methylprednisolone. Reports of acute toxicity and/or death following overdose of glucocorticoids are rare. In the event of overdose, no specific antidote is available; treatment is supportive and symptomatic. Methylprednisolone is haemodialysable.

5 PHARMACOLOGICAL PROPERTIES

5.1 Pharmacodynamic properties

Pharmacotherapeutic group: Glucocorticosteroids, ATC Code H02AB04

Methylprednisolone is a synthetic glucocorticoid and a methyl derivative of prednisolone. Methylprednisolone is a potent anti-inflammatory agent with the capacity to profoundly inhibit the immune system.

Glucocorticoids act primarily by binding to and activating intracellular glucocorticoid receptors. Activated glucocorticoid receptors bind to promoter

regions of DNA (which may activate or suppress transcription) and activate transcription factors resulting in inactivation of genes through deacetylation of histones.

Following corticosteroid administration there is a delay of several hours for the clinical effects resulting from changes in gene expression to be seen. Other effects not related to gene expression may be more immediate.

Corticosteroids influence the kidney and fluid and electrolyte balance, lipid, protein, and carbohydrate metabolism, skeletal muscle, the cardiovascular system, the immune system, the nervous system, and the endocrine system. Corticosteroids are also critical in the maintenance of function during stress.

5.2 Pharmacokinetic properties

Methylprednisolone pharmacokinetics is linear, independent of route of administration.

Absorption:

Methylprednisolone is rapidly absorbed and the maximum plasma methylprednisolone concentration is achieved around 1.5 to 2.3 hours across doses following oral administration in normal healthy adults. The absolute bioavailability of methylprednisolone in normal healthy subjects is generally high (82% to 89%) following oral administration.

Distribution:

Methylprednisolone is widely distributed into the tissues, crosses the blood-brain barrier, and is secreted in breast milk. Its apparent volume of distribution is approximately 1.4 L/kg.

The plasma protein binding of methylprednisolone in humans is approximately 77%.

Metabolism:

Corticosteroids are metabolised mainly in the liver but also in the kidney and are excreted in the urine.

In humans, methylprednisolone is metabolized in the liver to inactive metabolites; the major ones are 20 α -hydroxymethylprednisolone and 20 β -hydroxymethylprednisolone.

Metabolism in the liver occurs primarily via the CYP3A4 enzyme. (For a list of drug interactions based on CYP3A4-mediated metabolism, see section 4.5.)

Methylprednisolone, like many CYP3A4 substrates, may also be a substrate for the ATP-binding cassette (ABC) transport protein p-glycoprotein, influencing tissue distribution and interactions with other medicines.

Elimination:

The mean elimination half-life for total methylprednisolone is in the range of 1.8 to 5.2 hours. Total clearance is approximately 5 to 6 mL/min/kg.

5.3 Preclinical safety data

Based on conventional studies of safety pharmacology and repeated dose toxicity, no unexpected hazards were identified. The toxicities seen in repeated-dose studies were those expected to occur with continued exposure to exogenous adrenocortical steroids.

Mutagenic potential:

Methylprednisolone has not been formally evaluated for genotoxicity. Studies using structurally related analogues of methylprednisolone showed no evidence of a potential for genetic and chromosome mutations in limited studies in bacteria and mammalian cells.

Carcinogenic potential:

Methylprednisolone has not been formally evaluated in rodent carcinogenicity studies. Variable results have been obtained with other glucocorticoids tested for carcinogenicity in mice and rats. However, published data indicate that several related glucocorticoids including budesonide, prednisolone, and triamcinolone acetonide can increase the incidence of hepatocellular adenomas and carcinomas after oral administration in drinking water to male rats. These tumorigenic effects occurred at doses which were less than the typical clinical doses on a mg/m^2 basis. The clinical relevance of these findings is unknown.

Reproductive toxicity:

Methylprednisolone has not been evaluated in animal fertility studies. Adverse effects on fertility in male rats administered corticosterone were observed and were reversible. Decreased weights and microscopic changes in prostate and seminal vesicles were observed. The numbers of implantations and live fetuses were reduced and these effects were not present following mating at the end of the recovery period.

An increased frequency of cleft palate was observed among the offspring of mice treated during pregnancy with methylprednisolone in doses similar to those typically used for oral therapy in humans.

An increased frequency of cardiovascular defects and decreased body weight were observed among the offspring of pregnant rats treated with methylprednisolone in a dose that was similar to that used for oral therapy in humans but was toxic to the mothers. In contrast, no teratogenic effect was noted in rats with doses <1-18 times those typically used for oral therapy in humans in another study. High frequencies of foetal death and a variety of central nervous system and skeletal anomalies were reported in the offspring of pregnant rabbits treated with methylprednisolone in doses less than those used in humans. The relevance of these findings to the risk of malformations in human infants born to mothers treated with methylprednisolone in pregnancy is unknown. Safety margins for the reported teratogenic effects are unknown.

6 PHARMACEUTICAL PARTICULARS

6.1 List of excipients

Lactose

Sucrose
Maize starch
Mineral oil
Calcium stearate

6.2 Incompatibilities

Not applicable.

6.3 Shelf life

5 years.

6.4 Special precautions for storage

Store below 25°C.

6.5 Nature and contents of container

High density polyethylene bottles with tamper evident caps. Each bottle contains 14 tablets.

20-25 micron hard tempered aluminium foil/lacquer, 250 micron clear polyvinyl chloride film blister. Pack contains 30 tablets.

Not all pack sizes may be marketed.

6.6 Special precautions for disposal

No special requirements.

7 MARKETING AUTHORISATION HOLDER

Pfizer Limited
Ramsgate Road
Sandwich
Kent
CT13 9NJ
United Kingdom

8 MARKETING AUTHORISATION NUMBER(S)

PL 00057/1479

**9 DATE OF FIRST AUTHORISATION/RENEWAL OF THE
AUTHORISATION**

Date of first authorisation: 19 April 1989

Date of latest renewal: 1 February 2005

10 DATE OF REVISION OF THE TEXT

06/06/2017